SH PHARMA announced that the company plans to jointly acquire the equity of SH PHARMA held by Hutchmed (China) through a designated entity of Shanghai Jinfeng Jianfu Private Equity Management Co., Ltd. SH PHARMA intends to use its own funds of 0.995 billion yuan to acquire 10% of the equity. After the transaction is completed, SH PHARMA will hold a total of 60% equity in Hutchmed (China) and will consolidate it. This transaction does not constitute a significant asset reorganization as defined by the Regulations on Significant Asset Restructuring of Listed Companies.